News articles about Corbus Pharmaceuticals (NASDAQ:CRBP) have been trending somewhat positive recently, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.2606459428519 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Morning Stock Review: Corbus Pharmaceuticals Holdings, Inc … – Nasdaq Express (nasdaqexpress.com)
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Price to Earnings (P/E) Evaluation – Nasdaq Journal (nasdaqjournal.com)
- TESARO (TSRO) and Corbus Pharmaceuticals (CRBP) Financial Review (americanbankingnews.com)
- Corbus Pharmaceuticals (CRBP) Given a $32.00 Price Target by Cantor Fitzgerald Analysts (americanbankingnews.com)
- Corbus Pharmaceuticals (CRBP) Downgraded by BidaskClub to “Sell” (americanbankingnews.com)
CRBP stock opened at $6.25 on Friday. The firm has a market capitalization of $382.80, a price-to-earnings ratio of -9.62 and a beta of 2.09. Corbus Pharmaceuticals has a fifty-two week low of $5.30 and a fifty-two week high of $9.95.
Several equities analysts recently weighed in on CRBP shares. Raymond James Financial started coverage on shares of Corbus Pharmaceuticals in a report on Friday, January 19th. They issued an “outperform” rating and a $24.00 price target on the stock. Noble Financial reiterated a “buy” rating on shares of Corbus Pharmaceuticals in a report on Saturday, December 23rd. Cantor Fitzgerald set a $32.00 price objective on Corbus Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, March 12th. BidaskClub upgraded Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, ValuEngine upgraded Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $25.75.
In other news, Director David P. Hochman bought 5,000 shares of the company’s stock in a transaction on Wednesday, March 14th. The stock was bought at an average cost of $6.67 per share, with a total value of $33,350.00. Following the transaction, the director now directly owns 459,500 shares in the company, valued at approximately $3,064,865. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have purchased a total of 12,145 shares of company stock valued at $81,680 over the last three months. Corporate insiders own 11.90% of the company’s stock.
WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3295378/corbus-pharmaceuticals-crbp-receives-media-sentiment-rating-of-0-11.html.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.